$Aquestive Therapeutics(AQST.US)$ NEWS Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Positive Successful completion of Phase 3 study for Anaphylm in Q1 2024 Received FDA approval for Libervant for patients ages two to five Extended cash runway into 2026 through underwritten public offering Progressed clinical studies for AQST-108 in dermatology conditions Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024 Negati...
Mod Tan :
i have encounter before with other FDA approve and the stock dip 25% and in about 2-3 weeks it shot back up and its time to close positions. Just don't panic. The stock was shorted.
Mod Tan :
There was a stock ticker ccxi and before FDA approve many people who did stop loss got caught off guard from 22 went down to 12 and immediately shot back up to 23. The stock was then halted pending FDA announcement. After FDA approve it when up 35-39.
$Aquestive Therapeutics(AQST.US)$📣 FDA Approves Libervant™ (Diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 ⇨ 🥇 1st and only FDA approved orally administered rescue product ⇨ for Tx of seizure clusters (ages 2-5)
Breakthrough in Pediatric Epilepsy Treatment: FDA Approves Libervant™ for Seizure Clusters in Young Children. Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Libervant™ (diazepam) Buccal Film. This innovative treatment is designed for the acute management of seizure clusters in pediatric patients aged 2 to 5 years with epilepsy. This milestone marks Liber...
Aquestive Therapeutics股票讨论区
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
📣 4 PDUFAs upcoming in May:
$德纳维制药(DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$施贵宝(BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4制药(XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
🗓️ Last week’s PDUFAs:
$辉瑞(PFE.US)$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US)$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US)$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US)$ : CRL 4/22 🙁
⚠...
in Pediatric Patients Ages 2 to 5
⇨ 🥇 1st and only FDA approved orally administered rescue product
⇨ for Tx of seizure clusters (ages 2-5)
Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Libervant™ (diazepam) Buccal Film. This innovative treatment is designed for the acute management of seizure clusters in pediatric patients aged 2 to 5 years with epilepsy. This milestone marks Liber...
暂无评论